02.03.2026
Egle Therapeutics and Consortium Partners Awarded €8 Million Grant from Horizon Europe to Advance Clinical Development of EGL-001 in Neoadjuvant Head and Neck Cancer
...(United Kingdom), Vall d'Hebron Institute of Oncology (VHIO) (Spain), Gustave Roussy (France), and Technical University of Dresden (Germany) to conduct a multicenter, randomized, open-label Phase 1/2 neoadjuvant...
Quelle: smb.prentissheadlight.com